Synairgen (LON:SNG) Trading 4.4% Higher – Here’s What Happened

Synairgen plc (LON:SNG)’s stock price traded up 4.4% on Wednesday . The stock traded as high as GBX 2.03 ($0.03) and last traded at GBX 2.03 ($0.03). 228,663 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 2,145,702 shares. The stock had previously closed at GBX 1.95 ($0.02).

Synairgen Price Performance

The business has a 50-day moving average of GBX 2.96 and a two-hundred day moving average of GBX 3.71. The company has a current ratio of 6.77, a quick ratio of 6.35 and a debt-to-equity ratio of 0.09. The firm has a market cap of £4.10 million, a P/E ratio of -67.80 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).